Theratechnologies Inc T.TH

Alternate Symbol(s): THTX

Healthcare Biotechnology

Theratechnologies Inc. is a Canada-based clinical-stage biopharmaceutical company. The Company is focused on the development and commercialization of therapies addressing unmet medical needs. It markets prescription products for people with human immunodeficiency viruses (HIV) in the United States. The Company's research pipeline focuses on specialized therapies addressing unmet medical needs in HIV, nonalcoholic steatohepatitis (NASH) and oncology. Its medicines include Trogarzo and EGRIFTA SV (tesamorelin for injection). Trogarzo (ibalizumab-uiyk) injection is a long-acting monoclonal antibody which binds to domain 2 of the CD4 T cell receptors. EGRIFTA SV (tesamorelin for injection) is approved in the United States for the reduction of excess abdominal fat in people with HIV who have lipodystrophy. Its portfolio includes Phase I clinical trial of sudocetaxel zendusortide (TH1902), a novel peptide-drug conjugate (PDC), in patients with advanced ovarian cancer.

TSX:TH - Post by User

Theratechnologies Inc > ASCO June 2023

<< Previous

Bullboard Posts

Next >>

Comment by SPCEO1on Apr 30, 2023 2:23pm

153 Views

Post# 35421727

RE:ASCO June 2023

I suspect we would all like to see some phase 1b data at this time but it will still be interesting to see what they have to say in this presentation on the phase 1a data. Something is better than nothing but the phase 1b data is what really matters as it may give us greater insight into what the critical restarted trial will have to overcome. Of course, it seemed like the phase 1b may have also had some difficulties, so perhaps we will learn more about whatever they were and that may prove informative.